Latest KROS reports update at 2024-05-08: 2024-Q12023-Q42023-Q1
Keros Therapeutics logo
Keros Therapeutics KROS
$ 57.6 -1.1%

Keros Therapeutics EBITDA per Share 2011-2024 | KROS

Annual EBITDA per Share Keros Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-5.74 -4.52 -2.4 -2.09 - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-2.09 -5.74 -3.69

Quarterly EBITDA per Share Keros Therapeutics

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-1.35 - - - -1.36 - -1.07 -1.28 -1 - -0.85 -0.67 -0.68 - -0.58 -0.61 -4.2 - -0.93 -1.12 -1.25 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-0.58 -4.2 -1.21